Risk of severe infections in patients with triple-negative breast cancer treated with atezolizumab plus nab-paclitaxel: a real-world, postmarketing database study in Japan
Overall, our results did not indicate a significant increase in the risk of severe infections with atezolizumab plus nab-paclitaxel in daily clinical practice. Further research is required.
Authors
- Akira Murayama
- Akinori Yuri
- Haruo Sugano
- Kana Yamada (ORCID: https://orcid.org/0000-0003-1328-6477)
- Sayuri Nakane (ORCID: https://orcid.org/0009-0001-2733-3265)
- Masahiko Aoki (ORCID: https://orcid.org/0000-0001-7310-8280)
- Yuki Miyano
- Erika Nakatsuji
Institutions
- Chugai Pharma (United States) (US)
Publication Details
- Journal
- International Journal of Clinical Oncology
- Published
- 2025-10-30
- DOI
- https://doi.org/10.1007/s10147-025-02904-0
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Chugai Pharmaceutical